用于治疗呼吸系统疾病的双靶点PDE3/4抑制剂研究进展

Research progress on dual PDE3/4 inhibitors for the treatment of respiratory diseases

慢性阻塞性肺病和哮喘是以气道阻塞为主要表现的复杂炎症性疾病,已成为严重影响人类健康的呼吸道常见疾病。与临床单独使用PDE3或PDE4抑制剂相比,双靶点PDE3/4抑制剂具有协同的抗炎和支气管扩张作用,近年来引起广泛关注。本文综述目前处于临床前和临床研究阶段的双靶点PDE3/4抑制剂代表性研究成果,总结其最新进展及用于治疗慢性阻塞性肺病和哮喘的潜力。

Chronic obstructive pulmonary disease and asthma are complex inflammatory diseases with airway obstruction as the main characteristics,and have become common respiratory diseases that seriously affect human health.Compared with the clinical use of PDE3 or PDE4 inhibitors alone,dual PDE3/4 inhibitors have synergistic anti-inflammatory and bronchodilator effects,and have attracted widespread attention in recent years.This article reviews the representative research results of dual PDE3/4 inhibitors currently in the preclinical and clinical research stages,summarizing their latest progress and their potential for the treatment of chronic obstructive pulmonary disease and asthma.